Description
Rituxan Hycela (rituximab/hyaluronidase human) 1400mg and 23400 Units Single-Dose Vial **Refrigerated Item**
Rituxan hycela is a chemotherapy drug that is used to treat a range of cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. It is a monoclonal antibody, which means that it is designed to target and destroy a specific type of cell. Rituxan hycelA works by binding to the surface of cancer cells and destroying them. This can be a very effective treatment for cancer, but it can also cause some side effects, such as nausea and vomiting.
RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:
– Follicular Lymphoma (FL) (1.1)
- Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single- agent maintenance therapy
- Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
– Diffuse Large B-cell Lymphoma (DLBCL) (1.2)
- Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
– Chronic Lymphocytic Leukemia (CLL) (1.3)
- Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)
